PDL BioPharma announces U.S. launch of authorized generic of Tekturna

PDL BioPharma announces the U.S. commercial launch of an authorized generic of Tekturna, aliskiren hemifumarate 150 mg and 300 mg tablets. The authorized generic has the same drug formulation as Tekturna. The launch is being carried out by Prasco, LLC, d/b/a Prasco Laboratories, under an agreement with PDL’s wholly owned subsidiary, Noden Pharma USA. Noden will continue to manufacture and commercialize prescription aliskiren products under the Tekturna and Tekturna HCT brands in the United States, and the Rasilez and Rasilez HCT brands in international markets. The authorized generic launch does not include Tekturna HCT.
https://thefly.com/landingPageNews.php?id=2873995